Ani Pharmaceuticals (ANIP) Non-Current Assets (2010 - 2026)

Ani Pharmaceuticals has disclosed Non-Current Assets across 17 years of filings, most recently posting $674.9 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $674.9 million, down 10.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.8 billion (up 6.38% YoY), and the FY2025 annual result was $687.3 million, down 9.09% from the prior year.
• Non-Current Assets came in at $674.9 million for Q1 2026 at Ani Pharmaceuticals, down from $687.3 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $766.1 million in Q3 2024 to a low of $365.3 million in Q2 2024.
• The 5-year median for Non-Current Assets is $429.7 million (2022), against an average of $536.8 million.
• Across the five-year window, Non-Current Assets jumped 102.68% in 2025 and retreated 10.75% in 2026, its largest moves.
• Ani Pharmaceuticals' Non-Current Assets stood at $415.8 million in 2022, then dropped by 7.51% to $384.6 million in 2023, then soared by 96.57% to $756.0 million in 2024, then declined by 9.09% to $687.3 million in 2025, then fell by 1.8% to $674.9 million in 2026.
• The last three Non-Current Assets figures came in at $674.9 million (Q1 2026), $687.3 million (Q4 2025), and $709.8 million (Q3 2025), per Business Quant data.